HALO Precision Diagnostics

Germany-based Bayer (ETR: BAYN) has announced a strategic partnership with US radiology expert HALO Precision Diagnostics to jointly develop gadoquatrane, a late-stage contrast agent candidate. This collaboration focuses on advancing three Phase III studies aimed at evaluating the pharmacokinetics, safety, and efficacy of this gadolinium-based molecule in both adults and…